Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results
Molecularly adapted R-CHOP-X is feasible and associated with high response rates and favorable two-year survival in newly diagnosed DLBCL, comparing favorably with historical R-CHOP outcomes in high-risk populations. Expanded genomic panels substantially improve molecular classifiability. These findings warrant validation in larger, multicenter, randomized clinical trials.
Authors
- И. С. Абрамов (ORCID: https://orcid.org/0000-0002-6954-1564)
- Hasmik Mkrtchyan
- Tatiana Semina (ORCID: https://orcid.org/0000-0002-5873-8919)
- Natalia Bodunova (ORCID: https://orcid.org/0000-0001-6045-7334)
- Mariana Lysenko
- Tatiana Tolstykh
- Sergey Andreev
- Olga Kochneva
- Georgii Tyshkevich
- Liliia Shimanovskaia
- Sergej Rodnikov
- Dmitry Lebedev
- Viktoriia Basova
- Tatiana Chudnova
- Elena Baryakh
- Mariia Orlova
- Diana Ivanova
- Natalia Bekreneva
- Кseniya Tsurkina
- Marat Mingalimov
- Andrey Misyurin
- Laura Kesaeva
- Mikhail Donskoy (ORCID: https://orcid.org/0009-0007-1757-4683)
- Saida Gadzhieva
- Ekaterina Zotina
- Elena Misyurina
- Inna Samsonova
Institutions
- Sechenov University (RU)
- European University at Saint Petersburg (RU)
- Moscow Clinical Scientific Center (RU)
- Central State Medical Academy (RU)
- Russian Medical Academy of Continuous Professional Education (RU)
- Research Centre for Medical Genetics (RU)
- Vavilov Institute of General Genetics (RU)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-14
- DOI
- https://doi.org/10.3390/jcm15082983
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00